Spondyloarthritis & psoriatic arthritis
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort
Main finding · BASDAI, ASDAS, DAPSAResult — go to the resultMean difference (ΔBASDAI) −2.11Authors' conclusion
The short-term effectiveness of guselkumab in patients with PsA and suggestive features of axial involvement were shown.
Study context
- Population
- PsA patients with suggestive features of axial involvement (age 53.4 ± 11.2 years, male sex 26.9%), June 2022–June 2023
- Participants
- 67 patients
- Exposure
- Before vs after guselkumab administration
- Guselkumabn = 67
- Outcome
- Effectiveness by BASDAI, ASDAS, DAPSA and achievement of BASDAI ≤ 4
- Follow-up
- 4 months
Methodological detailsmulticentre, real-life
- Multicentre
- Real-life
Main finding
BASDAI, ASDAS, DAPSA
Mean difference (ΔBASDAI)
−2.11
By group
Guselkumab
52.2%
As reported in the abstract
Observational data: associations, not effects.
Further findings
MRI sacroiliac joints: reduction of 0.80 or larger in sacroiliac joint lesion score (MRI subgroup, n=27) · 4 months
- Patients with reduction ≥0.80 in sacroiliac joint lesion score, paralleling clinical response
- 70.3%
- 27 patients assessed by MRI before and after guselkumab
Safety
Minor adverse events, mainly injection site reactions
- Patients reporting minor adverse events
- 17.9%
Life-threatening side effects
- None recorded
Original publication
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort. Rheumatology (Oxford). Published 10 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →